VARIVAX™

BIOLOGICAL6 trials

Sponsors

Merck Sharp & Dohme LLC, GC Biopharma Corp

Conditions

Chickenpox VaccinePneumococcal InfectionsPneumococcal VaccinesVaricellaVaricella (Chickenpox)

Phase 3

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

CompletedNCT03620162

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2018-10-18End: 2020-12-14Updated: 2023-01-17

Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)

CompletedNCT03843632

Merck Sharp & Dohme LLCVaricella

Start: 2019-03-01End: 2020-06-19Updated: 2021-04-06

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

CompletedNCT03893448

Merck Sharp & Dohme LLCPneumococcal Infections, Pneumococcal Vaccines

Start: 2019-06-19End: 2021-05-24Updated: 2023-07-28

Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)

CompletedNCT04016714

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2019-08-28End: 2021-10-29Updated: 2023-05-06

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Not yet recruitingNCT07054099

GC Biopharma CorpChickenpox Vaccine, Varicella (Chickenpox)

Start: 2026-03-31End: 2036-07-31Target: 474Updated: 2025-07-11

Unknown Phase

Re-examination Study For Varivax (V210-059 AM2)

CompletedNCT01062061

Merck Sharp & Dohme LLCVaricella

Start: 2007-06-30End: 2012-05-31Updated: 2015-09-04

Related Papers

An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants

Expert Review of Vaccines2023-10-176 citations

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)

Vaccine2023-01-0141 citations

A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).

2022-12-1312 citations

Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy infants, children, and adolescents

Human Vaccines & Immunotherapeutics2021-10-263 citations

Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults

Human Vaccines & Immunotherapeutics2021-09-021 citations